Shanghai OPM Biosciences (688293) Stock Overview
Provides cell culture media and CDMO services in China and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
688293 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Shanghai OPM Biosciences Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥48.92 |
| 52 Week High | CN¥67.80 |
| 52 Week Low | CN¥31.85 |
| Beta | 0.72 |
| 1 Month Change | -13.06% |
| 3 Month Change | -4.00% |
| 1 Year Change | 27.70% |
| 3 Year Change | -36.37% |
| 5 Year Change | n/a |
| Change since IPO | -46.17% |
Recent News & Updates
Recent updates
After Leaping 47% Shanghai OPM Biosciences Co., Ltd. (SHSE:688293) Shares Are Not Flying Under The Radar
Nov 21
Weak Statutory Earnings May Not Tell The Whole Story For Shanghai OPM Biosciences (SHSE:688293)
Nov 07Shanghai OPM Biosciences' (SHSE:688293) Weak Earnings May Only Reveal A Part Of The Whole Picture
May 06Optimistic Investors Push Shanghai OPM Biosciences Co., Ltd. (SHSE:688293) Shares Up 28% But Growth Is Lacking
Mar 04Shareholder Returns
| 688293 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | 8.3% | 4.7% | 1.8% |
| 1Y | 27.7% | -0.3% | 26.5% |
Return vs Industry: 688293 exceeded the CN Biotechs industry which returned -0.3% over the past year.
Return vs Market: 688293 exceeded the CN Market which returned 26.5% over the past year.
Price Volatility
| 688293 volatility | |
|---|---|
| 688293 Average Weekly Movement | 6.3% |
| Biotechs Industry Average Movement | 5.1% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in CN Market | 10.1% |
| 10% least volatile stocks in CN Market | 3.2% |
Stable Share Price: 688293 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 688293's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 64 | Zhihua Xiao | www.opmbio.com |
Shanghai OPM Biosciences Co., Ltd. provides cell culture media and CDMO services in China and internationally. The company offers cell culture media and feed supplements, such as OPM's CHO-Platform, OPM-293 Platform, and VegaCHO media and feeds, as well as customized cell culture media development services. It also provides end-to-end biologics CDMO services, such as antibody discovery, stable cell line development, cell banking, upstream process development, downstream process development, formulation development, and quality control and product characterization of biologics.
Shanghai OPM Biosciences Co., Ltd. Fundamentals Summary
| 688293 fundamental statistics | |
|---|---|
| Market cap | CN¥6.51b |
| Earnings (TTM) | CN¥41.70m |
| Revenue (TTM) | CN¥354.91m |
Is 688293 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 688293 income statement (TTM) | |
|---|---|
| Revenue | CN¥354.91m |
| Cost of Revenue | CN¥0 |
| Gross Profit | CN¥354.91m |
| Other Expenses | CN¥313.21m |
| Earnings | CN¥41.70m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
Apr 23, 2026
| Earnings per share (EPS) | 0.32 |
| Gross Margin | 100.00% |
| Net Profit Margin | 11.75% |
| Debt/Equity Ratio | 2.8% |
How did 688293 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/11 09:10 |
| End of Day Share Price | 2026/03/11 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Shanghai OPM Biosciences Co., Ltd. is covered by 4 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Liangbi Zhao | China Galaxy Securities Co., Ltd. |
| Pei Cheng | China Galaxy Securities Co., Ltd. |
| Qianli Ma | Guosen Securities Co., Ltd. |